International Scholarly Research Notices

Clinical Study

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

Table 2

Colposcopic evaluation of patients.


TLA (mm²)	Patients
TLA (mm²)	01	02	03	04	05	06	07

Initial	244.93	493.68	608.98	638.98	481.71	30.8	291.96
1 month	0 (100%)	462.46 (6.32%)	486.72 (20.07%)	0 (100%)	75.70	0 (100%)	182.10 (37.62%)
2 months	0 (100%)	441.12 (10.64%)	381.8 (37.3%)	0 (100%)	48.15	0 (100%)	149.78 (48.69%)
3 months	0 (100%)	403.2 (18.32%)	286.61 (52.93%)	0 (100%)	0 (100%)	0 (100%)	104.73 (64.12%)

Response status	CR	SD	PR	CR	CR	CR	PR

Abbreviations
TLA: total lesion area.
TLA: total lesion area.
Complete response (CR) was considered as disappearance of all initial TLA; (PR) partial response if at least a 30% decrease of the initial TLA; progressive disease (PD) meant at least a 20% increase of the initial TLA and as stable disease (SD) if a reduction or an increase of the TLA compared to the initial value that is not enough for classification of the outcome as partial response or progressive disease.
.